HYPOXIC PULMONARY VASOCONSTRICTION IN SYSTEMIC-SCLEROSIS AND PRIMARY PULMONARY-HYPERTENSION

被引:57
作者
MORGAN, JM
GRIFFITHS, M
DUBOIS, RM
EVANS, TW
机构
[1] NATL HEART & LUNG INST,DEPT CARDIOL & INTENS CARE,LONDON,ENGLAND
[2] ROYAL BROMPTON HOSP,LONDON,ENGLAND
关键词
D O I
10.1378/chest.99.3.551
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Reduction of pulmonary vascular resistance by a high inspired oxygen concentration is a common, but not universal phenomenon in patients with pulmonary vascular disease of varying etiology that may determine their response to long-term domiciliary oxygen therapy. We therefore determined changes in PVR during oxygen therapy in two patient populations not previously studied: systemic sclerosis (n = 8, mean age +/- SEM, 44.5 +/- 5.4 years) and primary pulmonary hypertension (n = 7, mean age +/- SEM 38 +/- 7.8 years). All patients were hypoxemic (arterial oxygen tension, on air 9.5 +/- 1.2 kPa for SSc and 8.3 +/- 0.6 kPa for PPH, p > 0.05). Right atrial pressure, pulmonary artery pressure, pulmonary artery occlusion pressure, systemic arterial pressure, PaO2 and cardiac output by thermodilution were measured at three, 20-min intervals while inspiring air and again after inspiring 60 percent oxygen for 30 min. The PVR fell significantly with oxygen in patients with SSc from 797.6 +/- 179.2 to 610 +/- 151.6 dynes/s/cm-5 (p < 0.01), and this fall correlated with baseline PAP and PaO2 prior to oxygen therapy (r = 0.86, p < 0.025; r = 0.77, p < 0.05, respectively). In patients with PPH, there was no significant fall in PVR with oxygen (from 969 +/- 80.2 to 851.9 +/- 91.2 dynes/s/cm-5, p > 0.05) and no predictor of a vasodilator response in individual patients. In SSc, hypoxic pulmonary vasoconstriction contributes more consistently to elevated PVR than in patients with PPH.
引用
收藏
页码:551 / 556
页数:6
相关论文
共 20 条
[1]  
[Anonymous], 1981, LANCET, V1, P681
[2]  
BALDWIN ED, 1949, MEDICINE, V28, P1
[3]  
CRISPIN AR, 1963, BRIT J RADIOL, V38, P705
[4]  
Euler US v, 1946, ACTA PHYSL SCAND, V12, P301, DOI [DOI 10.1111/J.1748-1716.1946.TB00389.X, 10.1111/j.1748-1716.1946.tb00389.x]
[5]   CLINICAL-EXPERIENCE WITH THE OXYGEN CONCENTRATOR [J].
EVANS, TW ;
WATERHOUSE, J ;
HOWARD, P .
BRITISH MEDICAL JOURNAL, 1983, 287 (6390) :459-461
[6]   PRIMARY PULMONARY-HYPERTENSION - LENGTH OF SURVIVAL IN PATIENTS REFERRED FOR HEART-LUNG TRANSPLANTATION [J].
GLANVILLE, AR ;
BURKE, CM ;
THEODORE, J ;
ROBIN, ED .
CHEST, 1987, 91 (05) :675-681
[7]  
HUNG JM, 1989, THORAX, V44, P930
[8]  
LEE J, 1967, AM REV RESPIR DIS, V96, P1173
[9]  
LINDSAY DA, 1972, AM REV RESPIR DIS, V105, P242
[10]  
MORRISON DA, 1986, AM REV RESPIR DIS, V133, P390